STOCK COMPARISON
Sunmax Biotechnology Co vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Sunmax Biotechnology Co (4728) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Sunmax Biotechnology Co as the less overvalued of the two: Sunmax Biotechnology Co trades at TWD 389 versus a fair value of TWD 293 (-25%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Sunmax Biotechnology Co
4728.TWO · TWD · Health Care
-25%
upside to fair value
overvalued
PriceTWD 389
Fair ValueTWD 293
Quality87/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Sunmax Biotechnology CoVertex Pharmaceuticals
Valuation
28.1×P/E (TTM)28.8×
10.01×P/S (TTM)10.06×
12.61×P/B6.59×
18.6×EV/EBITDA23.8×
—PEG1.72×
3.2%Dividend yield—
TWD 12.10Dividend per share—
Profitability
36%Net margin36%
52%Operating margin38%
63%Return on equity24%
26%Return on assets12%
Growth
2%Revenue growth (YoY)8%
13.1%Avg. growth/yr (3Y)10.6%
18.8%Avg. growth/yr (5Y)14.2%
Balance & size
—Debt / equity0.03×
$634MMarket cap$123B
healthyGrowth qualityhealthy
Sunmax Biotechnology Co leads: 9 to 2 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Sunmax Biotechnology Coof which business quality 85 · market factors 57
Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
94
72
Quality GrowthAre margins and returns improving?
63
65
CashflowEarnings quality: real cash, not paper profit
84
79
Fin. StrengthBalance sheet, leverage, solvency risk
100
92
InvestmentDisciplined investing over empire-building
76
58
Low VolatilityCalm price path (market factor)
92
86
MomentumPrice trend over the last 3–12 months (market factor)
42
54
52W MomentumDistance to the 52-week high (market factor)
42
59
Net IssuanceBuybacks instead of dilution
82
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Sunmax Biotechnology Co
DCF ModelsTWD 462
Earnings-BasedTWD 341
Dividend DiscountTWD 204
MultiplesTWD 213
Asset-BasedTWD 19.90
Growth DCFTWD 334
Economic ProfitTWD 148
Growth EarningsTWD 444
18 of 26 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
18 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Sunmax Biotechnology Co
Bear TWD 220Fair Value TWD 293Bull TWD 403
TWD 389 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Sunmax Biotechnology Co · Health Care
Quality score87 · Top 25%
Fair value upside-25% · above median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-44% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Sunmax Biotechnology Co as the less overvalued of the two: Sunmax Biotechnology Co trades at TWD 389 versus a fair value of TWD 293 (-25%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Sunmax Biotechnology Co has the higher quality score (87/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
